Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FOXO Technologies Inc. (FOXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/22/2025: FOXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -38.53% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.99M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.25 | 52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 |
52 Weeks Range 0.17 - 13.00 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.25 |
Earnings Date
Report Date 2025-06-26 | When After Market | Estimate - | Actual -0.368 |
Profitability
Profit Margin -159.67% | Operating Margin (TTM) -48.8% |
Management Effectiveness
Return on Assets (TTM) -17.5% | Return on Equity (TTM) -1754.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11925576 | Price to Sales(TTM) 0.28 |
Enterprise Value 11925576 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 1.65 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 10620600 | Shares Floating 6482011 |
Shares Outstanding 10620600 | Shares Floating 6482011 | ||
Percent Insiders 2.19 | Percent Institutions 0.47 |
Upturn AI SWOT
FOXO Technologies Inc.
Company Overview
History and Background
FOXO Technologies Inc. was founded with the goal of understanding and mitigating the effects of aging through epigenetic analysis. It is focused on life insurance and longevity science.
Core Business Areas
- Life Insurance Products: FOXO offers life insurance policies that leverage epigenetic data to offer more personalized and potentially more affordable rates. These policies aim to incentivize healthy lifestyles and preventative care.
- Epigenetic Testing Services: FOXO provides epigenetic testing services to assess biological age and risk factors associated with aging. These tests are used both within their insurance products and as standalone services.
- Data Analytics and Research: The company conducts research and development related to epigenetics and longevity, using data collected from its testing and insurance services to further its understanding of aging and related diseases.
Leadership and Structure
The leadership team includes executives with backgrounds in insurance, biotechnology, and data science. The organizational structure supports both its insurance and research divisions.
Top Products and Market Share
Key Offerings
- FOXO Longevity Report: Provides a personalized epigenetic age assessment. Market share data is not publicly available. Competitors include companies like Elysium Health, Tally Health, and InsideTracker.
- FOXO Life Insurance: Life insurance products tailored to epigenetic markers. Market share data is unavailable. Competitors include traditional life insurance companies, but none focusing solely on epigenetic life insurance.
Market Dynamics
Industry Overview
The life insurance industry is undergoing a shift toward personalized risk assessment, driven by advancements in genetics and data analytics. The longevity and anti-aging market is experiencing rapid growth.
Positioning
FOXO aims to disrupt the life insurance industry by using epigenetic data to create more accurate risk profiles and incentivize healthy lifestyles. It is positioned as a pioneer in epigenetic-based life insurance.
Total Addressable Market (TAM)
The total addressable market for life insurance in the US is estimated to be in the trillions of dollars. The TAM for longevity-related products and services is also substantial and growing. FOXO's position is niche but has the potential for growth in personalization of life insurance.
Upturn SWOT Analysis
Strengths
- Innovative use of epigenetic data
- Potential for personalized risk assessment
- Focus on longevity and healthy lifestyles
Weaknesses
- Limited brand recognition
- Dependency on epigenetic technology validation
- Regulatory hurdles
- Limited capital
Opportunities
- Partnerships with healthcare providers
- Expansion of epigenetic testing services
- Growing interest in longevity and anti-aging
- Potential for premium pricing for individuals that show a longer life expectancy based on DNA profile.
Threats
- Competition from established insurance companies
- Changes in regulations regarding genetic testing
- Ethical concerns related to epigenetic data
- Technology becoming obsolete.
Competitors and Market Share
Key Competitors
- LTC
- PRU
- SLF
Competitive Landscape
FOXO's advantage lies in using epigenetic data, however it faces challenges competing with established insurers who have greater financial resources and brand awareness. It's smaller in size, which limits marketing efforts.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess due to the company's recent public listing.
Future Projections: Future projections are speculative and depend on the company's ability to scale its operations and secure partnerships.
Recent Initiatives: Recent initiatives include expanding its sales force and improving the company's technology and testing.
Summary
FOXO Technologies Inc. is a relatively new player seeking to disrupt life insurance using epigenetic data. It has an innovative approach, but its success hinges on proving the reliability of epigenetic testing for risk assessment. The company faces competition from larger insurers with greater resources and brand recognition. Scaling the business and navigating regulatory hurdles will be critical for its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Market Research Reports, Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FOXO Technologies Inc.
Exchange NYSE MKT | Headquaters West Palm Beach, FL, United States | ||
IPO Launch date 2021-01-29 | CEO, Interim CFO, Interim Principal Accounting Officer & Director Mr. Seamus Lagan | ||
Sector Healthcare | Industry Health Information Services | Full time employees 102 | Website https://www.foxotechnologies.com |
Full time employees 102 | Website https://www.foxotechnologies.com | ||
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.